Literature DB >> 18076371

Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.

Patrizia Carpinelli1, Jürgen Moll.   

Abstract

Aurora kinases are key regulators of mitosis and inhibitors being developed by a wide range of pharmaceutical and biotechnology companies for the treatment of cancer. Tumor cells respond differentially on inhibition of different Aurora kinase family members and these differences have to be considered in the clinical development of small-molecule inhibitors with respect to the chosen indications, the schedules or the selection of appropriate end points and they should also guide the development of biomarkers. Preclinical validation of potential biomarkers for Aurora kinase inhibitors led to a first application in clinical trials, as exemplified for the phosphorylation of histone H3 to follow Aurora-B inhibition. This review discusses the criteria for translation into the clinic and the value of pharmacodynamic biomarkers and their potential, but also their limitations to be used as surrogate markers for clinical end points.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18076371     DOI： 10.1517/14728222.12.1.69

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


  16 in total

1.  Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Authors:  Gary K Schwartz; Richard D Carvajal; Rachel Midgley; Scott J Rodig; Paul K Stockman; Ozlem Ataman; David Wilson; Shampa Das; Geoffrey I Shapiro
Journal:  Invest New Drugs       Date:  2012-06-02       Impact factor: 3.850

Review 2.  Aurora kinases in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Barbara Burtness; Igor Astsaturov; Erica A Golemis
Journal:  Lancet Oncol       Date:  2013-09       Impact factor: 41.316

3.  A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Authors:  Manik Amin; Susan E Minton; Patricia M LoRusso; Smitha S Krishnamurthi; Cheryl A Pickett; Jared Lunceford; Darcy Hille; David Mauro; Mark N Stein; Andrea Wang-Gillam; Lauren Trull; A Craig Lockhart
Journal:  Invest New Drugs       Date:  2015-12-01       Impact factor: 3.850

4.  Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.

Authors:  Jennifer R Diamond; Bruno R Bastos; Ryan J Hansen; Daniel L Gustafson; S Gail Eckhardt; Eunice L Kwak; Shuchi S Pandya; Graham C Fletcher; Todd M Pitts; Gillian N Kulikowski; Mark Morrow; Jamie Arnott; Mark R Bray; Carolyn Sidor; Wells Messersmith; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2010-12-03       Impact factor: 12.531

5.  Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

Authors:  Loredana Santo; Teru Hideshima; Diana Cirstea; Madhavi Bandi; Erik A Nelson; Gullu Gorgun; Scott Rodig; Sonia Vallet; Samantha Pozzi; Kishan Patel; Christine Unitt; Matt Squires; Yiguo Hu; Dharminder Chauhan; Anuj Mahindra; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Journal:  Clin Cancer Res       Date:  2011-03-23       Impact factor: 12.531

Review 6.  Protein kinase inhibitors against malignant lymphoma.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

7.  Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Authors:  Jennifer R Diamond; S Gail Eckhardt; Aik Choon Tan; Timothy P Newton; Heather M Selby; Kelsey L Brunkow; Maria I Kachaeva; Marileila Varella-Garcia; Todd M Pitts; Mark R Bray; Graham C Fletcher; John J Tentler
Journal:  Clin Cancer Res       Date:  2012-11-07       Impact factor: 12.531

8.  The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

Authors:  Amir Faisal; Lynsey Vaughan; Vassilios Bavetsias; Chongbo Sun; Butrus Atrash; Sian Avery; Yann Jamin; Simon P Robinson; Paul Workman; Julian Blagg; Florence I Raynaud; Suzanne A Eccles; Louis Chesler; Spiros Linardopoulos
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

9.  Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Authors:  A S Moore; A Faisal; D Gonzalez de Castro; V Bavetsias; C Sun; B Atrash; M Valenti; A de Haven Brandon; S Avery; D Mair; F Mirabella; J Swansbury; A D J Pearson; P Workman; J Blagg; F I Raynaud; S A Eccles; S Linardopoulos
Journal:  Leukemia       Date:  2012-02-22       Impact factor: 11.528

10.  Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Authors:  Hernan Carol; Ingrid Boehm; C Patrick Reynolds; Min H Kang; John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; Jianrong Wu; Amy E Wozniak; Yu Yang; Mark Manfredi; Jeffrey Ecsedy; Jianmin Wang; Geoffrey Neale; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Cancer Chemother Pharmacol       Date:  2011-03-30       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.